LENZ
LENZ Therapeutics Inc.

1,153
Loading...
Loading...
News
all
press releases
LENZ Therapeutics, Inc. (LENZ) is a Great Momentum Stock: Should You Buy?
Does LENZ Therapeutics, Inc. (LENZ) have what it takes to be a top stock pick for momentum investors? Let's find out.
Zacks·2mo ago
News Placeholder
More News
News Placeholder
Does LENZ Therapeutics, Inc. (LENZ) Have the Potential to Rally 30.86% as Wall Street Analysts Expect?
The consensus price target hints at a 30.9% upside potential for LENZ Therapeutics, Inc. (LENZ). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Zacks·2mo ago
News Placeholder
Blindness-Focused LENZ Therapeutics' Investigational Eye Drop Ready To Revolutionize Presbyopia Landscape, Analyst Says
Advances in presbyopia treatment with LENZ Therapeutics' LNZ100. Clinically proven to enhance near-vision for up to 10 hours, it offers a promising alternative to reading glasses. Analysts predict a...
Benzinga·1y ago
News Placeholder
LENZ Therapeutics gains as eye therapy succeeds in late-stage trial
LENZ Therapeutics gains as eye therapy succeeds in late-stage trial...
SeekingAlpha.com: All News·1y ago
News Placeholder
Lenz Therapeutics announces results from Phase 3 CLARITY study
See the rest of the story here. thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...
The Fly·1y ago
News Placeholder
LENZ Therapeutics Announces Positive Topline Data from Phase 3 CLARITY Presbyopia Trials
LENZ Therapeutics, Inc. (Nasdaq: LENZ or LENZ or the Company), a late clinical-stage biopharmaceutical company focused on developing the first aceclidine-based eye drop to improve near vision in...
Business Wire·1y ago
News Placeholder
LENZ Therapeutics to Host Investor Call to Discuss Topline Results from the Phase 3 CLARITY Presbyopia Trials
LENZ Therapeutics, Inc. (Nasdaq: LENZ or LENZ or the Company), a late clinical-stage biopharmaceutical company focused on developing the first aceclidine-based eye drop that has been shown to improve...
Business Wire·1y ago
News Placeholder
Huge Insider Buying From Buffett, an NFL Team Owner, a New CEO
Yet again, the Oracle of Omaha has bolstered his stake in a media giant's tracking stocks. However, Warren Buffett was not the only one making notable insider purchases in the past week or so. An NFL...
24/7 Wall St.·1y ago
News Placeholder
LENZ Therapeutics Announces Completion of Merger with Graphite Bio and Provides Update on Recent Clinical and Corporate Progress
LENZ Therapeutics, Inc. (Nasdaq: LENZ) (LENZ or the Company), a late clinical-stage biopharmaceutical company focused on developing the first aceclidine-based eye drop that has been shown to improve...
Business Wire·1y ago

Latest LENZ News

View

Advertisement. Remove ads.

Advertisement. Remove ads.

Advertisement. Remove ads.